

肺癌

抗癌藥物治療指引

討論日期

- 團隊討論：105 年 11 月 29 日
- 三院討論：105 年 12 月 7 日
- 團隊確認：106 年 12 月 13 日
- 核備日期：106 年 4 月 18 日

Small Cell Lung Cancer

Chemotherapy as primary or adjuvant therapy

Limited stage (maximum of 4-6 cycles):

During chemotherapy + RT, cisplatin/etoposide is recommended

The use of myeloid growth factors is not recommended during CCRT

參考文獻 1,2

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	60~80	1	Q3W	4~6
Etoposide	100	1~3	Q3W	4~6

參考文獻 3

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5~6 AUC	1	Q3W	4~6
Etoposide	100	1, 2, 3	Q3W	4~6

Extensive stage (maximum of 4-6 cycles)

參考文獻 4,5

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75~80	1	Q3W	4~6
Etoposide	100	1~3	Q3W	4~6

參考文獻 6

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5~6 AUC	1	Q3W	4~6
Etoposide	100	1, 2, 3	Q3W	4~6

Subsequent chemotherapy:

Relapse <6 months, PS 0-2:

參考文獻 7,8

藥品名	劑量 /m ²	給藥日	頻率
Topotecan	1.5 (IV)	1~5	Q3W
	2.3 (PO)	1~5	Q3W

參考文獻 7

藥品名	劑量 /m ²	給藥日	頻率
Cyclophosphamide	1000	1	Q3W
Doxorubicin	45	1	Q3W
Vincristine	2	1	Q3W

Consider dose reductions versus growth factors in the poor performance status patient.

參考文獻

1. Turrisi AT 3rd, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 1999;340(4):265-271.
2. Saito H, Takada Y, Ichinose Y, et al. Phase II study of etoposide and cisplatin with concurrent twice-daily thoracic radiotherapy followed by irinotecan and cisplatin in patients with limited-disease small-cell lung cancer: West Japan Thoracic Oncology Group 9902. J Clin Oncol 2006;24(33): 5247-5252.
3. Skarlos DV, Samantas E, Briassoulis E, et al. Randomized comparison of early versus late hyperfractionated thoracic irradiation concurrently with chemotherapy in limited disease small-cell lung cancer: a randomized phase II study of the Hellenic

- Cooperative Oncology Group (HeCOG). *Ann Oncol* 2001;12(9):1231-1238.
4. Spigel R, Townley PM, Waterhouse DM, et al. Randomized phase II study of bevacizumab in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer: results from the SALUTE trial. *J Clin Oncol* 2011;29:2215-2222.
 5. Niell HB, Herndon JE, Miller AA, et al. Randomized phase III Intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte-colony stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B trial 9732. *J Clin Oncol* 2005;23:3752-3759.
 6. Okamoto H, Watanabe K, Nishiwaki Y, et al. Phase II study of area under the plasmaconcentration-versus-time curve-based carboplatin plus standard-dose intravenous etoposide in elderly patients with small cell lung cancer. *J Clin Oncol* 1999;17(11):3540-3545.
 7. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. *J Clin Oncol* 1999;17(2):658-667.
 8. O'Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. *J Clin Oncol*. 2006;24:5441-5447.

Non-Small Cell Lung Cancer

Chemotherapy regimens for neoadjuvant and adjuvant therapy

參考文獻 1-3

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75~80	1	Q3W	4
Vinorelbine	25~30	1, 8	Q3W	4

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75~80	1	Q3W	4
Vinorelbine	40~60	1, 8	Q3W	4

參考文獻 4

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	60~75	1	Q3W	4
Gemcitabin	1250	1, 8	Q3W	4

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	60~75	1	Q3W	4
Docetaxel	60~75	1	Q3W	4

參考文獻 6

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	60~75	1	Q3W	4
Pemetrexed	500	1	Q3W	4

藥品名	劑量 /m ²	給藥日	頻率
UFUR	100		QD
	200		QD

Chemotherapy regimens used with radiation therapy

Concurrent chemotherapy/RT regimens

Regimens can be used as neoadjuvant/preoperative/induction chemoradiotherapy

Regimens can be used as adjuvant or definitive concurrent chemotherapy/RT

參考文獻 7,8

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	50	1, 8	Q4W	2
Etoposide	50	1~5	Q4W	2

參考文獻 9

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5 AUC	1	Q3W	4
Pemetrexed	500	1	Q3W	4

參考文獻 10

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75	1	Q3W	3
Pemetrexed	500	1	Q3W	3
± Pemetrexed	500	1	Q3W	additional 4 cycles

參考文獻 11

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	45~50	1	QW	2
Carboplatin	2 AUC	1	QW	2
± Paclitaxel	200	1		additional 2 cycles
± Carboplatin	6 AUC	1		additional 2 cycles

Sequential chemotherapy/RT regimens (Adjuvant)

參考文獻 12

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	200	1	Q3W	2
Carboplatin	6 AUC	1	Q3W	2

Concurrent chemotherapy/RT followed by chemotherapy

Regimens can be used as adjuvant or definitive concurrent chemotherapy/RT

參考文獻 12

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	45~50	1	QW	2
Carboplatin	2 AUC	1	QW	2
followed by				
Paclitaxel	200	1	Q3W	2
Carboplatin	6 AUC	1	Q3W	2

參考文獻

1. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-lung cancer. N Engl J Med 2005;352:2589-2597.
2. Arriagada R, Bergman B, Dunant A, et al. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based

- adjuvant chemotherapy in patients with completely resected non-small cell lung cancer. *N Engl J Med* 2004;350:351-360.
3. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIa non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. *Lancet Oncol* 2006;7:719-727.
 4. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol* 2012;30:3516-3524.
 5. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX326 study group. *J Clin Oncol* 2003;21:3016-3024.
 6. Kreuter M, Vansteenkiste J, Fishcer JR, et al. Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study. *Ann Oncol* 2013;24:986-992.
 7. Albain KS, Crowley JJ, Turrisi AT III, et al. Concurrent cisplatin, etoposide, and chest radiotherapy in pathologic stage IIIB non-small-cell lung cancer: A Southwest Oncology Group Phase II Study, SWOG 9019. *J Clin Oncol* 2002;20:3454-3460.
 8. Curran WJ Jr, Paulus R, Langer CJ, et al. Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410. *J Natl Cancer Inst.* 2011;103:1452-1460.
 9. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011;29:3120-3125.
 10. Choy H, Gerber DE, Bradley JD, et al. Concurrent pemetrexed and radiation therapy in the treatment of patients with inoperable stage III non-small cell lung cancer: a systematic review of completed and ongoing studies. *Lung Cancer* 2015;87:232-240.
 11. Bradley JD, Paulus R, Komaki R, et al. Standard-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIa or IIIB non-small-cell lung cancer (RTOG 0617): a randomized, two-by-two factorial phase 3 study. *Lancet Oncol* 2015;16:187-199.

12. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. *J Clin Oncol.* 2005;23:5883-5891.

Target therapy

EGFR-mutation-positive

參考文獻 1

藥品名	劑量 /m ²	給藥日	頻率
Erlotinib	150 mg		QDAC

參考文獻 2

藥品名	劑量 /m ²	給藥日	頻率
Afatinib	40 mg		QDAC

參考文獻 3

藥品名	劑量 /m ²	給藥日	頻率
Gefitinib	250 mg		QD

ALK positive

參考文獻 4

藥品名	劑量 /m ²	給藥日	頻率
Crizotinib	250 mg		BID

參考文獻

1. Product Information: TARCEVA(R) oral tablets, erlotinib oral tablets. OSI Pharmaceuticals, LLC (per FDA), Farmingdale, NY, 2013.
2. Product Information: GILOTRIF(TM) oral tablets, afatinib oral tablets. Boehringer Ingelheim Pharmaceuticals, Inc. (per FDA), Ridgefield, CT, 2013.
3. Product Information: IRESSA(R) oral tablets, gefitinib oral tablets. AstraZeneca Pharmaceuticals (per FDA), Wilmington, DE, 2015.
4. Product Information: XALKORI(R) oral capsules, crizotinib oral capsules. Pfizer Labs (per FDA), New York, NY, 2013.

Systemic therapy for advanced or metastatic disease

First-line systemic therapy options

Adenocarcinoma, large cell, NSCLC NOS (PS 0-1)

參考文獻 1

藥品名	劑量 /m ²	給藥日	頻率	週期
Bevacizumab	15 mg/kg	1	Q3W	≥6
Carboplatin	6 AUC	1	Q3W	≤6
Paclitaxel	200	1	Q3W	≤6

參考文獻 2

藥品名	劑量 /m ²	給藥日	頻率	週期
Bevacizumab	15 mg/kg	1	Q3W	≥4
Carboplatin	6 AUC	1	Q3W	4
Pemetrexed	500	1	Q3W	≥4

參考文獻 3

藥品名	劑量 /m ²	給藥日	頻率	週期
Bevacizumab	7.5 mg/kg		Q3W	*
Cisplatin	75		Q3W	
Pemetrexed	500		Q3W	

參考文獻 4

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥6
Albumin-bound Paclitaxel	100	1,8,15	QW	≥6

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC		Q3W	≥6
Docetaxel	75		Q3W	≥6

參考文獻 6

藥品名	劑量 /m ²	給藥日		
Carboplatin	325	1		
Etoposide	100	1~3		

參考文獻 7

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	4/5/5 AUC	1	Q4W	1/2/3
Etoposide	50 mg PO BID	1~14/14/21	Q4W	(additional 3 cycles as 3rd)

參考文獻 8

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5 AUC	1	Q4W	≤4
Gemcitabine	1000	1,8,15	Q4W	≤4

參考文獻 9

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥3
Paclitaxel	200	1	Q3W	≥3

參考文獻 10

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥6
Pemetrexed	500	1	Q3W	≥6

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75		Q3W	≥6
Docetaxel	75		Q3W	≥6

參考文獻 11

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	100	1	Q3W	≥6
Etoposide	100	1~3	Q3W	≥6

參考文獻 9

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	80	1	Q3W	≥3
Gemcitabine	1000	1, 8	Q3W	≥3

參考文獻 12

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75	1	Q3W	≤6
Gemcitabine	1250	1, 8	Q3W	≤6

參考文獻 13

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75	2	Q3W	
Paclitaxel	135	1	Q3W	

參考文獻 12

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75	1	Q3W	≤6
Pemetrexed	500	1	Q3W	≤6

參考文獻 14

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	≤8
Docetaxel	85	8	Q3W	≤8

參考文獻 15

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	2~6
Vinorelbine	25	1, 8	Q3W	2~6

Adenocarcinoma, large cell, NSCLC NOS (PS 2)
參考文獻 16

藥品名	劑量 /m ²	給藥日	頻率
Albumin-bound Paclitaxel	260		Q3W

參考文獻 17

藥品名	劑量 /m ²	給藥日	頻率
Albumin-bound Paclitaxel	100	1,8,15	Q4W

參考文獻 18

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥6
Albumin-bound Paclitaxel	100	1,8,15	QW	≥6

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC		Q3W	≥6
Docetaxel	75		Q3W	≥6

參考文獻 6

藥品名	劑量 /m ²	給藥日	頻率
Carboplatin	325	1	
Etoposide	100	1~3	

參考文獻 7

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	4/5/5 AUC	1	Q4W	1/2/3
Etoposide	50 mg PO BID	1~14/14/21	Q4W	(additional 3 cycles as 3rd)

參考文獻 8

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5 AUC	1	Q4W	≤4
Gemcitabine	1000	1,8,15	Q4W	≤4

參考文獻 9

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥3
Paclitaxel	200	1	Q3W	≥3

參考文獻 10

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥6
Pemetrexed	500	1	Q3W	≥6

參考文獻 19, 20

藥品名	劑量 /m ²	給藥日	頻率	週期
Docetaxel	75	1	Q3W	≤6

參考文獻 21

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1250	1, 8, 15	Q4W	8 (+2)

參考文獻 22, 23

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1250	1, 8	Q3W	≤6

參考文獻 14

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	≤8
Docetaxel	85	8	Q3W	≤8

參考文獻 15

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	2~6
Vinorelbine	25	1, 8	Q3W	2~6

參考文獻 24

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	225	1	Q3W	≤6

參考文獻 25, 26

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	80	1, 8, 15	Q4W	≤4

參考文獻 27

藥品名	劑量 /m ²	給藥日	頻率	週期
Pemetrexed	500	1	Q3W	

參考文獻

1. A. Sandler, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small lung cancer. *N Engl J Med* 2006;355:2542-2550.
2. Patel JD, Socinski MA, Garon EB, et al. Pointbreak: a randomized phase III study of pemetrexed plus carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with stage IIIB or IV nonsquamous non-small cell lung cancer. *J Clin Oncol* 2013;31:3004-3011
3. Barlesi F, Scherpereel A, Rittmeyer A, et al. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small cell lung cancer: AVAPERL. *J Clin Oncol* 2013;31:3004-3011
4. Socinski MA, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062
5. Fossella F, Periera JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21(16):3016-3024.
6. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. *J Clin Oncol* 1990;8:1556-1562
7. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. *Gruppo Oncologico Cooperativo Sud-Italia. Eur J Cancer.* 1998;34:1710-1714.
8. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. *Cancer.* 2003;98:542-553.
9. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced nonsmall-cell lung cancer: Four-Arm Cooperative Study

- in Japan. *Ann Oncol* 2007;18:317-323.
10. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. *Clin Cancer Res*. 2005;11:690-696.
 11. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol* 1999;17:12-18.
 12. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. *J Clin Oncol* 2008;26:3543-3551.
 13. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. *N Engl J Med* 2002; 346:92-98.
 14. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610.
 15. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2005;49:233-240.
 16. Green MR, Manikhas GM, Orlov S, et al. Abraxane , a novel Cremophor -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol*. 2006;17:1263-1268.
 17. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26:639-643.
 18. Socinski MA1, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
 19. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362.
 20. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy

- with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol.* 2009;27:591-598
21. Zatloukal P, Kanitz E, Magyar P, Jassem J, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. *Lung Cancer.* 1998;22:243-250.
 22. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. *J Clin Oncol.* 2005;23:8380-8388.
 23. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol.* 2012;30:3516-24.
 24. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol.* 2005;23:190-196.
 25. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer.* 2004;44:231-239.
 26. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. *Oncology.* 2004;66:347-352.
 27. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. *J Clin Oncol.* 2004;22:1589-1597.

Systemic therapy for advanced or metastatic disease

First-line systemic therapy options

Squamous cell carcinoma (PS 0-2)

參考文獻 13

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≤6
Albumin-bound Paclitaxel	100	1,8,15	QW	≤6

參考文獻 1

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC		Q3W	≤4
Docetaxel	75		Q3W	≤4

參考文獻 4

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5 AUC	1	Q4W	≥4
Gemcitabine	1000	1, 8, 15	Q4W	≥4

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥3
Paclitaxel	200	1	Q3W	≥3

參考文獻 1

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75		Q3W	≤6
Docetaxel	75		Q3W	≤6

參考文獻 6

藥品名	劑量 /m ²	給藥日	頻率
Cisplatin	100	1	Q3W
Etoposide	100	1~3	Q3W

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	80	1	Q3W	≥3
Gemcitabine	1000	1, 8	Q3W	≥3

參考文獻 7

藥品名	劑量 /m ²	給藥日	頻率
Cisplatin	75	1	Q3W
Gemcitabine	1250	1, 8	Q3W

參考文獻 8

藥品名	劑量 /m ²	給藥日	頻率	週期
Cisplatin	75	2	Q3W	≤6
Paclitaxel	135	1	Q3W	≤6

參考文獻 9

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	≤8
Docetaxel	85	8	Q3W	≤8

參考文獻 10

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1000	1, 8	Q3W	2~6
Vinorelbine	25	1, 8	Q3W	2~6

參考文獻 11

藥品名	劑量 /m ²	給藥日	頻率	週期
Albumin-bound Paclitaxel	260		Q3W	

參考文獻 12, 13

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	
Albumin-bound Paclitaxel	100	1, 8, 15	QW	

參考文獻 1

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC		Q3W	≤4
Docetaxel	75		Q3W	≤4

參考文獻 2

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	325	1		
Etoposide	100	1~3		

參考文獻 3

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	4~5 AUC	1	Q4W	1/2/3
Etoposide	50	1~14/1~21	Q4W	(additional 3 cycles as 3rd)

參考文獻 4

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	5 AUC	1	Q4W	≤4
Gemcitabine	1000	1,8,15	Q4W	≤4

參考文獻 5

藥品名	劑量 /m ²	給藥日	頻率	週期
Carboplatin	6 AUC	1	Q3W	≥3
Paclitaxel	200	1	Q3W	≥3

參考文獻 14, 15

藥品名	劑量 /m ²	給藥日	頻率	週期
Docetaxel	75	1	Q3W	≤6

參考文獻 16

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1250	1, 8, 15	Q4W	8 (+2)

參考文獻 17, 18

藥品名	劑量 /m ²	給藥日	頻率	週期
Gemcitabine	1250	1, 8	Q3W	≤6

參考文獻 19

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	225	1	Q3W	≤6

參考文獻 20, 21

藥品名	劑量 /m ²	給藥日	頻率	週期
Paclitaxel	80	1, 8, 15	Q4W	≤4

參考文獻

1. Fossella F, Periera JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. *J Clin Oncol* 2003;21(16):3016-3024.
2. Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861. *J Clin Oncol* 1990;8:1556-1562.
3. Frasci G, Comella P, Panza N, et al. Carboplatin-oral etoposide personalized dosing in elderly non-small cell lung cancer patients. Gruppo Oncologico Cooperativo Sud-Italia. *Eur J Cancer*. 1998;34:1710-1714.
4. Danson S, Middleton MR, O'Byrne KJ, et al. Phase III trial of gemcitabine and carboplatin versus mitomycin, ifosfamide, and cisplatin or mitomycin, vinblastine, and cisplatin in patients with advanced nonsmall cell lung carcinoma. *Cancer*. 2003;98:542-553.
5. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small cell lung cancer: Four-Arm Cooperative Study in Japan. *Ann Oncol* 2007;18:317-323.
6. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. *J Clin Oncol* 1999;17:12-18.
7. Scagliotti GV, Parikh P, von Pawel J, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naïve patients with advanced-stage NSCLC. *J Clin Oncol* 2008;26:3543-3551.
8. Schiller JH, Harrington D, Belani CP, et al. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung

- Cancer. *N Engl J Med* 2002; 346:92-98.
9. Pujol JL, Breton JL, Gervais R, et al. Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin. *Ann Oncol* 2005;16:602-610.
 10. Tan EH, Szczesna A, Krzakowski M, et al. Randomized study of vinorelbine--gemcitabine versus vinorelbine--carboplatin in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2005;49:233-240.
 11. Green MR, Manikhas GM, Orlov S, et al. Abraxane , a novel Cremophor -free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. *Ann Oncol*. 2006;17:1263-1268.
 12. Rizvi NA, Riely GJ, Azzoli CG, et al. Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. *J Clin Oncol*. 2008;26:639-643.
 13. Socinski MA1, Bondarenko I, Karaseva NA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. *J Clin Oncol* 2012;30:2055-2062.
 14. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. *J Clin Oncol* 2000;18:2354-2362.
 15. Fidias PM, Dakhil SR, Lyss AP, et al. Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer. *J Clin Oncol*. 2009;27:591-598.
 16. Zatloukal P, Kanitz E, Magyar P, Jassem J, et al. Gemcitabine in locally advanced and metastatic non-small cell lung cancer: the Central European phase II study. *Lung Cancer*. 1998;22:243-250.
 17. Sederholm C, Hillerdal G, Lamberg K, et al. Phase III trial of gemcitabine plus carboplatin versus single-agent gemcitabine in the treatment of locally advanced or metastatic non-small-cell lung cancer: the Swedish Lung Cancer Study Group. *J Clin Oncol*. 2005;23:8380-8388.
 18. Pérol M, Chouaid C, Pérol D, et al. Randomized, phase III study of gemcitabine or erlotinib maintenance therapy versus observation, with predefined second-line treatment, after cisplatin-gemcitabine induction chemotherapy in advanced non-small-cell lung cancer. *J Clin Oncol*. 2012;30:3516-24.
 19. Lilenbaum RC, Herndon JE 2nd, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell

- lung cancer: the cancer and leukemia group B (study 9730). *J Clin Oncol*. 2005;23:190-196.
20. Ceresoli GL, Gregorc V, Cordio S, et al. Phase II study of weekly paclitaxel as second-line therapy in patients with advanced non-small cell lung cancer. *Lung Cancer*. 2004;44:231-239.
 21. Yasuda K, Igishi T, Kawasaki Y, et al. Phase II study of weekly paclitaxel in patients with non-small cell lung cancer who have failed previous treatments. *Oncology*. 2004;66:347-352.

